We are live on ! Find out more
CYT

Cyteir Therapeutics, Inc. Common Stock
CYT

Delisted

CYT was delisted on the 15th of March, 2024.

Back to rankings

32 hedge funds and large institutions have $137M invested in Cyteir Therapeutics, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 6 increasing their positions, 8 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

380% more capital invested

Capital invested by funds: $28.5M → $137M (+$108M)

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

7% more funds holding

Funds holding: 30 → 32 (+2)

25% less repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 8

Holders
32
Holders Change
+2
Holders Change %
+6.67%
% of All Funds
0.51%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
7
Increased
6
Reduced
8
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BCM
BML Capital Management
Indiana
+$5.11M
2
AC
Aldebaran Capital
Indiana
+$246K
3
TCM
Tang Capital Management
California
+$162K
4
Morgan Stanley
Morgan Stanley
New York
+$154K
5
MAM
Marquette Asset Management
Minnesota
+$110K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$4.11M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$1.07M
3
CCM
CAAS Capital Management
New York
-$503K
4
Millennium Management
Millennium Management
New York
-$155K
5
NM
Newtyn Management
New York
-$109K
Name Holding Trade Value Shares
Change 		Change in
Stake
NHAS
1
Novo Holdings A/S
Denmark
$113M – – –
BCM
2
BML Capital Management
Indiana
$5.73M +$5.11M +3,146,296 New
OMC
3
OUP Management Company
Pennsylvania
$4.48M – – –
Fidelity Investments
4
Fidelity Investments
Massachusetts
$4.1M -$1.07M -656,045 -23%
APM
5
Avidity Partners Management
Texas
$3.21M -$51.5K -31,700 -2%
NM
6
Newtyn Management
New York
$1.73M -$109K -67,053 -7%
Vanguard Group
7
Vanguard Group
Pennsylvania
$1.06M – – –
LCM
8
Laurion Capital Management
New York
$654K – – –
Renaissance Technologies
9
Renaissance Technologies
New York
$320K -$86.4K -53,159 -23%
AC
10
Aldebaran Capital
Indiana
$275K +$246K +151,239 New
CCM
11
CAAS Capital Management
New York
$274K -$503K -309,373 -67%
EWM
12
Evercore Wealth Management
New York
$267K – – –
Morgan Stanley
13
Morgan Stanley
New York
$228K +$154K +94,931 +314%
Geode Capital Management
14
Geode Capital Management
Massachusetts
$217K +$3.09K +1,900 +2%
RC
15
RBF Capital
California
$213K -$55.2K -33,987 -22%
TCM
16
Tang Capital Management
California
$182K +$162K +100,000 New
Millennium Management
17
Millennium Management
New York
$152K -$155K -95,590 -53%
BlackRock
18
BlackRock
New York
$148K +$3.09K +1,902 +2%
BCM
19
Bridgeway Capital Management
Texas
$127K -$81.2K -50,000 -42%
MAM
20
Marquette Asset Management
Minnesota
$124K +$110K +67,990 New
Bank of America
21
Bank of America
North Carolina
$123K +$69.4K +42,722 +172%
EC
22
EcoR1 Capital
California
$79.8K +$71.2K +43,823 New
Two Sigma Advisers
23
Two Sigma Advisers
New York
$47.3K – – –
State Street
24
State Street
Massachusetts
$43.4K – – –
CC
25
Cannell Capital
Wyoming
$35.8K – – –
1
2

CYT Hedge Fund Activity: Q1 2023 in Review

32 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Cyteir Therapeutics, Inc. Common Stock (CYT) for Q1 2023, worth a combined $137M — up 380% from $28.5M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new CYT positions and 5 closed out — a net gain of 2 holders — while 6 added to existing stakes and 8 trimmed.

The largest buyer was BML Capital Management, opening a new position worth an estimated $5.11M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $4.11M sold.

  • 32 institutional investors held Cyteir Therapeutics, Inc. Common Stock (CYT) as of Q1 2023, up from 30 in Q4 2022.
  • Funds reported $137M of Cyteir Therapeutics, Inc. Common Stock stock for Q1 2023, up 380% quarter-over-quarter.
  • 7 funds opened new Cyteir Therapeutics, Inc. Common Stock positions in Q1 2023 and 5 closed out, a net change of +2 holders.
  • The largest Cyteir Therapeutics, Inc. Common Stock buyer in Q1 2023 was BML Capital Management, an estimated $5.11M added.
  • The largest Cyteir Therapeutics, Inc. Common Stock seller in Q1 2023 was Baker Bros. Advisors, an estimated $4.11M sold.

Based on aggregated 13F filings for Q1 2023.